Omega-3 fatty acid supplementation Not Applicable
Conditions
Interventions
Patients are manually randomised by the hospital research pharmacist to one of four groups:
1. Omega-3 ethyl esters providing 230 mg EPA + 190 mg DHA
2. SMEDDS Omega-3
Sponsors
Pronova BioPharma
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy males and females 2. Age 18 to 65 years 3. Body mass index 20 to 35 kg/m2 4. Not consuming fish oil or similar supplements 5. Not eating more than one oily fish meal per week 6. Willing to adhere to the study protocol 7. Being able to provide written informed consent 8. Omega-3 index (EPA+DHA in red blood cells_ < 6.5 at screening
Exclusion criteria
Exclusion criteria: 1. Being diabetic (type 1 or type 2) 2. Being vegetarian or vegan and unwilling to consume capsules with a beef gelatine coating 3. Use of prescribed medicine to control inflammation 4. Smokers 5. Chronic gastrointestinal problems (e.g. IBD, IBS, celiac disease, cancer) 6. Allergic to fish 7. Allergic to soybean 8. Participation in another clinical trial (currently or in the 12 weeks prior to study entry) 9. Pregnancy or lactation 10. Blood donations during 3 months prior to or during the study period 11. Omega-3 index (EPA+DHA in red blood cells > 6.5 at screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of EPA and DHA in red blood cells, measured by gas chromatography at baseline, 1, 4 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Concentration of EPA and DHA in plasma and white blood cells, measured by gas chromatography at baseline, 1, 4 and 12 weeks | — |
Countries
England, United Kingdom
Outcome results
None listed